Producer
Jiangxi Guoyao Pharmaceutical (Guoyao Pharmaceutical Group)
Chinese pharmaceutical API manufacturer (HQ Jiangxi Province; part of Sinopharm/China National Pharmaceutical Group structure); produces penicillin G, 6-APA, and downstream semi-synthetic penicillin APIs. Jiangxi Guoyao represents the Chinese provincial pharmaceutical industry that produces the majority of global antibiotic APIs — a network of state-linked pharmaceutical manufacturers concentrated in Hebei, Jiangxi, and Shandong provinces that produce most of the world's penicillin, ampicillin, and amoxicillin.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Jiangxi Guoyao Pharmaceutical (Guoyao Pharmaceutical Group) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Jiangxi Guoyao Pharmaceutical (Guoyao Pharmaceutical Group) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Penicillin G (Fermentation)
40%Penicillin Nucleus (6-APA)
35%Downstream Antibiotic Formulations
25%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2022
Chinese penicillin fermentation producers including Jiangxi Guoyao collectively supply an estimated 80-90% of global penicillin G and 6-APA — the critical intermediates for virtually all penicillin and semi-synthetic penicillin antibiotics used worldwide (amoxicillin, ampicillin, etc.). China's dominance emerged from a combination of state investment in fermentation capacity in the 1970s-90s, subsequent privatization-era efficiency improvements, and structural cost advantages from cheap corn steep liquor fermentation nutrients and government-subsidized energy and land. Western antibiotic fermentation capacity was eliminated progressively from the 1980s through 2010s as Chinese production became uncompetitive to maintain. Today there is no meaningful penicillin G fermentation capacity in the United States, European Union, or Japan — any disruption to Chinese antibiotic API production (pandemic, export restriction, plant incident) would create immediate global shortages of antibiotics used to treat pneumonia, strep throat, UTIs, and other common infections. Jiangxi Guoyao is one node in this structurally concentrated Chinese antibiotic API production system.
U.S. Food and Drug Administration ↗Origin2023
Jiangxi Guoyao Pharmaceutical is part of the Sinopharm/China National Pharmaceutical Group (CNPGC) structure — a network of provincial state pharmaceutical enterprises linked to China's central pharmaceutical conglomerate. Jiangxi Province became a major antibiotic API production center in the 1970s-80s as China prioritized pharmaceutical self-sufficiency. The concentration of penicillin fermentation in Jiangxi and neighboring provinces (Hebei, Shandong) reflects the Cold War-era Chinese policy of building pharmaceutical capability in inland provinces away from coastal vulnerability. Chinese penicillin fermentation plants like Jiangxi Guoyao use corn steep liquor (a fermentation nutrient derived from corn wet-milling) as a key growth medium — linking penicillin production to corn processing in a supply chain dependency that runs from Midwestern US corn production through Chinese wet milling to Chinese antibiotic fermentation.
China National Pharmaceutical Group (Sinopharm) ↗